Advertisement

Topics

BIND Therapeutics, Inc. Company Profile

03:49 EDT 25th March 2019 | BioPortfolio

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer.


News Articles [885 Associated News Articles listed on BioPortfolio]

STAT Plus: Relay Therapeutics raises $400 million in venture capital funding

Relay makes movies of proteins in motion, which could help scientists better design medicines that could bind to protein targets.

Proteins use a lock and key system to bind to DNA

(Gladstone Institutes) Scientists have traditionally thought that DNA binding proteins use patterns in the genome's code of As, Cs, Ts, and Gs to guide them to the right location, with a given protein...

Seer Launches to Develop Liquid Biopsy for Cancer, Brain Disease

Omid Farokhzad has, as he says, “been around the block a few times” in biotech. The cancer nanomedicine researcher has cofounded a handful of companies that have tried to develop nanotech-based an...

Rare antibodies could be key ingredients in therapeutics capable of neutralizing many Ebola types

Two new studies by scientists at Scripps Research are bringing Ebola virus's weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and ...

Fluorescence-activating beta-barrel protein made from scratch for first time

For the first time, scientists have created, entirely from scratch, a protein capable of binding to a small target molecule. They designed a cylindrical protein called a beta barrel, which has a cavit...

New RNA Kits from Empirical Bioscience Offer Swift and Extensive Purification

Empirical Bioscience announce that they have introduced the EB Pure Total RNA Kit and the EB Pure DNase 1 Digestion Kit for the fast and reliable purification of RNA from cells or soft tissue. The Hig...

Empirical Bioscience’s New EB Pure Plasmid Mini-Prep Kit Offers High-Quality DNA in 30 Minutes or Less

Empirical Bioscience announced the introduction of a new EB Pure Plasmid Mini-Prep Kit today. The kit combines the power of High-Bind technology with alkaline-SDS lysis of bacterial cells to deliver h...

Harpoon closes $15mm Series A

Harpoon Therapeutics Inc. (oncology) raised $15mm in its Series A round from affiliates of MPM Capital and the UBS Oncology Impact Fund. Harpoon was formed last year and is developing cancer therapies...

Drugs and Medications [38 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [618 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics.

The immunoglobulin superfamily protein lymphocyte-activation gene 3 (LAG-3) participates in immune suppression and has been identified as a suitable target for cancer therapies. In order to generate b...

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

Resetting the ligand binding site of placental protein 13/galectin-13 recovers its ability to bind lactose.

Placental protein-13 / galectin-13 (Gal-13) is highly expressed in placenta, where its lower expression is related to pre-eclampsia. Recently, the crystal structures of wild type Gal-13 and its varian...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

Clinical Trials [287 Associated Clinical Trials listed on BioPortfolio]

Long-Term Follow Up Study

The LTFU study will conduct a naturalistic follow up of the well characterized CAN-BIND study population of patients every six months and continuing over a five-year period. This will prov...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or squamous cel...

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Companies [1335 Associated Companies listed on BioPortfolio]

BIND Therapeutics

BIND Therapeutics is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND’s Me...

BIND Therapeutics, Inc.

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering pl...

BIND Therapeutics and Navidea Biopharmaceuticals

BIND Therapeutics is a clinical-stage nanomedicine platform company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration...

BIND Biosciences, Inc.

BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs to provide signif...

BIND Therapeutics and Synergy Pharmaceuticals

More Information about "BIND Therapeutics, Inc." on BioPortfolio

We have published hundreds of BIND Therapeutics, Inc. news stories on BioPortfolio along with dozens of BIND Therapeutics, Inc. Clinical Trials and PubMed Articles about BIND Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BIND Therapeutics, Inc. Companies in our database. You can also find out about relevant BIND Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record